|
|
|
|
|
|
Updating...
|
 |
| The Australian Tissue Engineering Centre |
| |
|
The Australian Tissue Engineering Centre Ltd (ATEC) is strategically located in Australia’s biotechnology hub in Melbourne. We provide pre-clinical testing services for drug and biomaterials development, and collaborative R&D in tissue engineering. ATEC is a uniquely collaborative facility, bringing together the knowledge and technical excellence of Australia’s world renowned Bernard O’Brien Institute of Microsurgery, the Australian Stem Cell Centre and the University of Melbourne, at the forefront of Tissue Engineering research. We provide uniquely powerful biological models for drug and biomaterials development, within a Quality management System about to be audited by NATA to meet the OECD Good Laboratory Practice (GLP) standard.
Alliances for cardiac, liver and pancreas organoid development, and improvements in the use of fat as a surgical filler.
Development of new human toxicology models based on organoids.
Development of animal models for difficult cancer xenografts based on vascularised chamber implants.
ATEC Ltd is an Australian tissue engineering company providing expert contract R&D and testing services to commercial and public-sector clients. ATEC offers technical excellence, and access to uniquely productive biological models.
Assays and models include quantification of angiogenesis in vitro and in vivo; cytotoxicity analyses; matrix development and formulation testing; and a variety of unique models for target tissue growth (including cardiac, pancreatic islet, adipose, and liver) in proprietary tissue engineering chambers in small and large animals. Stem cell isolation, propagation, and in vitro and in vivo differentiation analyses complement these tissue engineering models.
Human organoid models in nude rats and mice are in development, and ATEC is open to proposals for co-development.
Our primary focus is on organoid development, based on a proprietary vascularised chamber technology. This provides a platform for well-vascularised tissue development in a defined environment, using a variety of matrices and precursor cells. For example, we have produced beating cardiac muscle from cardiomyocyte precursors, and insulin-producing cells from islet precursors. The vascularised chamber also offers a defined environment for patient-proximal tumour propagation and agent testing. Myogel, a proprietary tissue engineering matrix, is highly adipogenic, and has applications in reconstructive surgery. To complement these technologies, we also offer a wide range of in vitro and in vivo assays and surgical models for drug discovery, and materials testing.
www.atecltd.com.au
 
| |
|
|
|
|
|
|
|